Monyan Pharma

About Monyan Pharma

Hubei Monyan Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company established in February 2009, specializing in the development, production, and sale of natural medicines and health foods. The company focuses on the oncology treatment sector, with a mission to improve the quality of life for cancer patients.

The company's main product is "Shengbai Oral Liquid," a national new drug developed by the renowned traditional Chinese medicine oncologist, Professor Shao Mengyang. This product, which has independent intellectual property rights and a national invention patent, is used to treat leukopenia (a reduction in white blood cells) caused by radiotherapy and chemotherapy in tumor patients, as well as to enhance general immunity. Another key product is the "Polyporus Polysaccharide Capsule," developed by Professor Zhang Ronglie of the China Academy of Chinese Medical Sciences, which is used in the treatment of chronic viral hepatitis B and tumors.

Monyan Pharma operates a business model that integrates the entire value chain, from the cultivation of Chinese medicinal materials to research and development, production, and sales. Its revenue is generated through the sale of its pharmaceutical products and health foods. The company has established a production base in Jingmen, Hubei, a TCM cultivation base in Ningshan, Shaanxi, and an innovative drug research and development center in Shanghai. The legal representative is Zhang Min. The company has received venture capital funding, including a Series B round in November 2023.